This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: Global Industry Analysts, Inc.
GIA announces the release of a comprehensive global report on Osteoporosis Therapeutics markets. The global market for Osteoporosis Therapeutics is forecast to reach US$10 billion by the year 2017. Increasing aging population worldwide, growing awareness of the disease, and development and introduction of novel therapeutics represent the major factors influencing the demand for Osteoporosis Therapeutics. Despite the fact that many of the existing drugs are set to lose patent protection, increasing number of pipeline drugs, which are in the late stage development, bodes well for the future growth prospect of the market.
San Jose, California (PRWEB) May 14, 2012
Follow us on LinkedIn – According to the World Health Organization (WHO), osteoporosis is the second leading healthcare problem. Afflicting more than 200 million people worldwide, osteoporosis poses a major clinical challenge to the medical world. The osteoporosis market is still largely untapped, with only about a third of osteoporosis patients being diagnosed and treated for the condition, which opens up a wide range of opportunities for the pharmaceutical companies. The osteoporosis therapeutic market comprises drugs that either enhance bone formation or minimize bone resorption. Various classes of drugs available for osteoporosis treatment include anabolic or bone forming drug class – recombinant human PTH (parathyroid hormone); and antiresorptive agents such as Bisphosphonates, Calcitonin, Estrogen, and SERMs (Selective Estrogen Receptor Modulators). Although widely in demand, these drugs possess significant drawbacks, either in the form of safety or efficacy. As a result, significant unmet needs persist in the market, which bodes immense potential for growth of efficacious and safer new drugs.
Presently, Bisphosphonates represents the most widely used therapeutic class in the treatment of osteoporosis worldwide. Fosamax (alendronate) of Merck led the market until 2008 before its sales began to plunge due to its patent expiry in early 2008. The entry of generic versions of Fosamax not only led to the significant drop in sales of Fosamax but also affected sales of other drugs in the Bisphosphonate drug class, such as Boniva and Actonel. This is primarily due to lower dosage differentiation between the drugs, in addition to lower efficacy of Boniva and Actonel compared to Fosamax as shown in clinical studies. Overall, sales of Bisphosphonate agents are expected to decline over the following years, with focus shifting towards SERMs and new drugs.
The US represents the largest regional market for osteoporosis therapeutics worldwide, as stated by the new market research report on Osteoporosis Therapeutics. Until recently, pharmaceutical companies in the US paid limited attention to osteoporosis, but now are scrambling for a share of what is turning out to be an enormous market. Ongoing research and development efforts in the field of osteoporosis therapeutics have led to the evolution of new genre of therapeutics, such as the anabolic agents. New developments and delivery methods are likely to offer improved treatment options and hope for patients. Europe trails behind the US. Limited awareness on osteoporosis and restricted availability of diagnostic equipment form the key factors plaguing the growth of osteoporosis therapeutics in Europe. Nevertheless, changing demographics throughout Europe have increased the potential for osteoporosis therapeutics.
Strong pipeline with significant number of drugs in the late stage development bodes prospective entry of new drugs into the market, even as many of the existing drugs lose patent protection. These new drugs include bone-tissue resorption inhibitors, SERMs (selective estrogen receptors modulators), cathepsin K inhibitors, and calcium modulators. Growth in the market is also expected to be driven by the recent approval of Denosumab, a monoclonal antibody recently approved for the treatment of osteoporosis. Denosumab has been approved in the US, EU, Switzerland, Canada, and Australia.
In the upcoming years, growth in the elderly population across the world, and the resultant increase in potential osteoporosis patients, is poised to offer several opportunities for pharmaceutical companies in the osteoporosis therapeutics market. However, with patents of several drugs set to expire, the value of existing treatment products is expected to decline by 2015. A whole new range of products set for launch in the near future would nevertheless offset the decline in revenues, and provide enormous growth potential in the osteoporosis therapeutics market in future. The osteoporosis market provides several opportunities for the existing as well as future companies. However, increase in cost pressure due to generic penetration is a major barrier for companies to enter this market. Leading companies in this industry continue to follow their direct-to-consumer promotional campaigns, while sponsoring events for increasing awareness of disorder and their respective treatment.
Major players profiled in the report include Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Wyeth, Sanofi SA, Servier SA, Unigene Laboratories Inc., Warner Chilcott Plc., among others.
The research report titled “Osteoporosis Therapeutics: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the osteoporosis therapeutics markets, current market trends, key growth drivers, overview of major drug classes, insight into current leading and pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for osteoporosis therapeutics market for the years 2009 through 2017 for the following geographic markets - US, Japan, Europe, and Rest of World. Key product segments analyzed include Bisphosphonates, ERT Drugs, SERMs, Calcitonins, MAB (Denosumab) and Others (including Anabolic/Bone-Forming agents such as Tereparatide). Also, a six-year (2003-2008) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebosteoporosis_therapeutics/bisphophonates/prweb9503923.htm